NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) said CFO Ian Somaiya and EVP Matthew Philippe will present in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 11:45 a.m. ET. A live webcast and archived replay will be available via the company investor relations site.

News Market Reaction – NAMS

+0.29%

+0.29% Session close to close

In the Apr 8 session, NAMS gained 0.29%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights NAMS’s continued engagement with the investment community via a Needham...

Analysis

This announcement highlights NAMS’s continued engagement with the investment community via a Needham fireside chat on April 13, 2026 at 11:45 a.m. ET. Historically, similar conference and presentation news has produced mixed reactions, with some events aligning with gains and others showing divergence. Investors may track how this communication complements prior updates on cash of $728.9M, ongoing Phase 3 programs, and recent regulatory filings, while keeping an eye on trading volumes and insider activity trends.

Key Figures

Conference date: April 13, 2026 Fireside chat time: 11:45 a.m. ET Conference edition: 25th Annual

3 metrics

Conference date April 13, 2026 Needham Virtual Healthcare Conference fireside chat

Fireside chat time 11:45 a.m. ET Scheduled time for NAMS virtual fireside chat

Conference edition 25th Annual Needham Virtual Healthcare Conference iteration

Historical Context

5 past events · Latest: Apr 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 02	Inducement grants	Neutral	+3.4%	Inducement equity awards for new hires under the 2024 Inducement Plan.
Mar 23	Clinical presentations	Positive	+3.7%	Three ACC.26 posters on obicetrapib outcomes and LDL-C–CVD risk data.
Mar 06	Inducement grants	Neutral	+3.0%	Equity grants for two non-executive hires with multi-year vesting.
Feb 25	IR conferences	Neutral	-2.8%	Management participation in multiple March investor conferences and webcasts.
Feb 18	Full-year results	Positive	+1.5%	FY2025 results, strong cash of $728.9M, MAAs accepted, ongoing Phase 3 trials.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent NAMS headlines, including earnings and scientific/IR updates, have often been followed by modest price gains, with occasional divergences on more routine corporate or conference news.

Recent Company History

Over the last few months, NAMS has issued a mix of corporate, clinical, and investor-relations updates. Inducement equity grants in March–April 2026 coincided with price gains of 3.43% and 3.05%, despite being largely administrative. A March ACC.26 presentation announcement preceded a 3.7% move higher, and full-year 2025 results with $728.9M cash and ongoing Phase 3 programs saw a 1.48% rise. By contrast, a February investor-conference participation release was followed by a -2.78% decline, showing that conference-related headlines can draw mixed reactions.

Key Terms

cardiovascular disease, low-density lipoprotein cholesterol

2 terms

cardiovascular disease medical

"patients at risk of cardiovascular disease (“CVD”) with elevated low-density li..."

A group of conditions that affect the heart and blood vessels, such as heart attacks, strokes and clogged arteries. Think of the cardiovascular system as a body’s plumbing and engine: when pipes narrow or the pump fails, treatment, devices and long-term care become necessary. Investors watch these diseases because their prevalence drives demand for drugs, devices and services, influences healthcare costs and insurer payouts, and affects workforce productivity and regulatory risk.

low-density lipoprotein cholesterol medical

"with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing ..."

A form of cholesterol carried in the blood that tends to deposit fatty material on artery walls, often called “bad” cholesterol; think of LDL as delivery trucks that sometimes drop sticky cargo along the body’s highways. Investors monitor LDL because drugs, medical devices, and diagnostic tests that change LDL levels or how they’re managed can drive healthcare spending, regulatory approvals, and company earnings, affecting valuations and risk in health-related businesses.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the 25^th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:45 a.m. ET.

A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

When will NewAmsterdam Pharma (NAMS) present at the Needham Virtual Healthcare Conference?

NewAmsterdam Pharma will present on April 13, 2026 at 11:45 a.m. ET. According to NewAmsterdam, CFO Ian Somaiya and EVP Matthew Philippe will participate in a virtual fireside chat and answer investor questions during the scheduled session.

How can investors watch the NewAmsterdam Pharma (NAMS) fireside chat on April 13, 2026?

Investors can watch the live webcast via the company investor relations site at ir.newamsterdampharma.com. According to NewAmsterdam, the webcast starts at 11:45 a.m. ET and an archived replay will be available on the company website after the event.

Who from NewAmsterdam Pharma (NAMS) will speak at the Needham conference presentation?

CFO Ian Somaiya and EVP, Head of Investor Relations Matthew Philippe will speak at the fireside chat. According to NewAmsterdam, both executives will discuss company developments and engage with investors during the virtual session on April 13, 2026.

Will a replay of the NewAmsterdam Pharma (NAMS) Needham presentation be available after April 13, 2026?

Yes. An archived replay will be posted on the company website after the live webcast. According to NewAmsterdam, the replay will remain accessible through the investor relations site for investors who cannot attend the live April 13, 2026 session.

What topics will NewAmsterdam Pharma (NAMS) likely cover in the April 13, 2026 fireside chat?

The company will discuss recent clinical and investor-focused developments relevant to its CVD pipeline. According to NewAmsterdam, the fireside chat led by its CFO and EVP of investor relations will focus on corporate updates and program status for patients with elevated LDL-C.